Internal Medicine, Hematology & Oncology · La Jolla, CA
NPI
1184680399
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
10666 N Torrey Pines Rd
La Jolla, CA, 92037
Phone (858) 554-9489
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.9M
187,297 services
Medicare patients, 2024
1,263
Average age 76
Drug cost, 2024
$9.0M
1,379 prescriptions
Company payments, 2025
$14K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alan Saven was code J9025 (injection, azacitidine, 1 mg), 48,695 times for 17 patients. In total Alan Saven billed 187,297 services in 134 codes, and Medicare paid $2.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-06-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9025 Injection, azacitidine, 1 mg | Office | 48,695 | 17 | $0.29 | $14K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 34,920 | 18 | $39.19 | $1.4M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 20,400 | 11 | $2.32 | $47K |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 4,690 | 24 | $16.14 | $76K |
| J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 4,320 | 17 | $38.60 | $167K |
| J0185 Injection, aprepitant, 1 mg | Office | 4,290 | 17 | $1.31 | $5,610 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 3,800 | 11 | $44.70 | $170K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 2,813 | 49 | $0.25 | $701 |
| 99214 Office E&M - Established | Office | 1,564 | 793 | $99.00 | $155K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 950 | 23 | $0.23 | $218 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 602 | 22 | $0.09 | $54.25 |
| 96375 Injection Administration | Office | 552 | 78 | $13.54 | $7,474 |
| 96413 Chemotherapy Administration | Office | 467 | 95 | $117.12 | $55K |
| 99215 Office E&M - Established | Office | 355 | 152 | $148.28 | $53K |
| 96365 Intravenous Infusion, Hydration | Office | 324 | 134 | $54.07 | $18K |
By year: 2022 $2.3M for 122,632 services; 2023 $2.6M for 152,016 services; 2024 $2.9M for 187,297 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alan Saven prescribed most often to Medicare patients was Hydroxyurea, with 257 prescriptions and refills. In total Alan Saven wrote 1,379 Medicare prescriptions that cost $9.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 257 | 644 | 69 | $8,089 |
| Lenalidomide Generic | 149 | 149 | 19 | $1.9M |
| Acyclovir Generic | 104 | 243 | 31 | $3,316 |
| Brukinsa Zanubrutinib | 70 | 70 | Under 11 | $1.0M |
| Jakafi Ruxolitinib Phosphate | 66 | 68 | Under 11 | $1.2M |
| Eliquis Apixaban | 64 | 137 | 17 | $79K |
| Revlimid Lenalidomide | 63 | 63 | 19 | $1.1M |
| Imbruvica Ibrutinib | 61 | 65 | Under 11 | $1.2M |
| Prochlorperazine Maleate Generic | 50 | 50 | 36 | $928 |
| Dexamethasone Generic | 45 | 67 | 19 | $1,192 |
| Prednisone Generic | 32 | 54 | 13 | $218 |
| Calquence Acalabrutinib Maleate | 26 | 32 | Under 11 | $273K |
| Ondansetron Hcl Generic | 26 | 26 | 16 | $295 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 22 | 22 | 15 | $234 |
| Doptelet Avatrombopag Maleate | 22 | 28 | Under 11 | $340K |
Brand drugs: - claims; generic drugs: 898 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alan Saven $14K ($14K in general payments such as food, travel and fees) from 8 companies. The largest payer was BeOne Medicines USA, Inc. with $13K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.